1. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Issue 10002 (10th October 2015) Authors: Tsimikas, Sotirios; Viney, Nicholas J; Hughes, Steven G; Singleton, Walter; Graham, Mark J; Baker, Brenda F; Burkey, Jennifer L; Yang, Qingqing; Marcovina, Santica M; Geary, Richard S; Crooke, Rosanne M; Witztum, Joseph L Journal: Lancet Issue: Volume 386:Issue 10002(2015) Page Start: 1472 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. (September 2020) Authors: Loomba, Rohit; Morgan, Erin; Watts, Lynnetta; Xia, Shuting; Hannan, Lisa A; Geary, Richard S; Baker, Brenda F; Bhanot, Sanjay Journal: Lancet gastroenterology and hepatology Issue: Volume 5:Number 9(2020) Page Start: 829 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Therapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia. (April 2015) Authors: Bell, Thomas A; Graham, Mark J; Baker, Brenda F; Crooke, Rosanne M Journal: Clinical lipidology Issue: Volume 10:Number 2(2015) Page Start: 191 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗